ADPT as reported
Adaptive Biotechnologies Corporation reported $308M of revenue over the trailing twelve months, +50% on the year before. 10 reported series are charted on this page, each one as filed.
$308M
Revenue, trailing twelve months · to Q2 2026 · +50% against the twelve months before
- Net Income
- −$64M
Net Income · −47% year on year · trailing twelve months to Q2 2026
- Free Cash Flow
- −$24M
Free Cash Flow · −71% year on year · trailing twelve months to Q2 2026
- Op Margin
- −14%
Op Margin · trailing twelve months to Q2 2026
| Series | Latest | Year on year | As of |
|---|---|---|---|
| Revenue | $308M | +50% | Q2 2026 |
| Net Income | −$64M | −47% | Q2 2026 |
| EPS | −$0.41 | −49% | Q2 2026 |
| Gross Margin | 75% | n/a | Q2 2026 |
| Op Margin | −14% | n/a | Q2 2026 |
| Net Margin | −23% | n/a | Q2 2026 |
| ROE | −33% | n/a | Q2 2026 |
| ROA | −12% | n/a | Q2 2026 |
| ROIC | −25% | n/a | Q2 2026 |
| Free Cash Flow | −$24M | −71% | Q2 2026 |
Every figure straight from the statements as filed with the SEC, no scoring, no adjustment. Open a series for its full history.
Adaptive Biotechnologies Corporation (ADPT) - Revenue & ProfitRevenue & ProfitAdaptive Biotechnologies Corporation (ADPT)
Revenue (TTM)Net Income (TTM)
Powered byryufin.com
Diagnostics & Research
Ranks #6 of 29 by Smart Score